← All stocks

Vanda Pharmaceuticals Inc.

VNDA Net selling

CIK 0001347178 #3500 in the set updated 19 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$2.82M

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$2.82M

6 of 6 sales

Net

−$2.82M

−$2.82M against sales at will

By person

12 insiders · 6 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Polymeropoulos Mihael Hristos

President and CEO

—

$1.28M (1)

−$1.28M

2,704,496

4.47%

$22.36M

+44.5%

Moran Kevin Patrick

SVP, CFO & Treasurer

—

$350.82K (1)

−$350.82K

411,380

0.6804%

$3.40M

+79.8%

Williams Timothy

SVP & General Counsel

—

$350.76K (1)

−$350.76K

377,450

0.6243%

$3.12M

+91.8%

Birznieks Gunther

SVP, Business Development

—

$350.73K (1)

−$350.73K

494,197

0.8174%

$4.08M

+57.6%

Wijkstrom Joakim

SVP, Chief Marketing Officer

—

$254.59K (1)

−$254.59K

333,469

0.5515%

$2.76M

+156.9%

Honore Tage

Director

—

$240.90K (1)

−$240.90K

135,069

0.2234%

$1.12M

+110.2%

DUGAN RICHARD W

Director

—

219,054

0.3623%

$1.81M

+85.3%

Chrousos Phaedra

Director

—

164,950

0.2728%

$1.36M

+157.2%

Ward Anne Sempowski

Director

—

160,667

0.2657%

$1.33M

+168.5%

Mitchell Stephen Ray

Director

—

112,846

0.1866%

$932.77K

+126.3%

McGuire Daniel Patrick

SVP, GC and Secretary

—

109,982

0.1819%

$909.10K

+266.8%

Duncan Charles Cliff

Director

—

98,701

0.1632%

$815.85K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 20

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 6

Transactions with no price 0

Shares from compensation/vesting 1,437,537

History held since 19 Sep 2016